Pediatric asthma treatment

Larenas‐Linnemann, Désirée; Vega, Margarita Fernández; Luna-Pech, Jorge A.; Rosas, Jimena Villaverde; Martell, José Antonio Ortega; Navarro, Blanca E. del Río; Salas, María del Carmen Cano; Lombard, Jade Romero; Estrada, Erika del Carmen López; Rodríguez-González, Mónica; Butrón, José Luis Mayorga; Hernández, Jorge Salas; Vázquez-García, Juan Carlos; Aldana, Ignacio; Becerra, Mario Humberto Vargas; Bedolla-Barajas, Martín; Pérez, Noel Rodríguez; Aranda, Ambrocio Aguilar; González, Carlos Adrián Jiménez; Bolaños, Carlos García; Galindo, Claudia Garrido; Mendoza-Hernández, David Alejandro; López, Enrique Mendoza; Pérez, Gerardo López; Gutierrez, Hector; Molina, H. León; Lanza, H. Martínez de la; Aguilar, Héctor Stone; Vera, Javier Gómez; Salinas, Jorge Olvera; Romero, José Luis Gálvez; Sáenz, José Santos Lozano; Gama, Juan Ignacio Salgado; Jiménez-Chobillón, Marcos Alejandro; Avilés, M.A. García; Balanzar, M.P. Guinto; Ávalos, Miguel Alejandro Medina; Angeles, Robert Camargo; Torrentera, Rogelio García; Freyre, Saraí Toral; Narvaez, Gabriel Montes; Gómez, Héctor Solorio; Peña, Juan Rosas; Tapia, S.J. Romero; Herrera, A. Reyes; Schacht, Francisco Cuevas; Flores, Joaquín Esquer; Hazouri, José Antonio Sacre; Martínez, Lorenzo Compean; Sánchez, Pablo J.; Salinas, Sergio Garza; Loyola, C. Baez; Alvarado, I. Romero; Reyes, José Luis Miguel; Espinosa, L.E. Huerta; Flores, Manuel Ángel Correa; Martínez, Ricardo Castro

doi:10.1016/j.anai.2018.03.008

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If step-up treatment is required, the prescription of moderate-dose ICS or LTRAs in combination with low-dose ICS is recommended for children aged <6 years. For children aged ≥6 years, the use of low-dose ICS in combination with long-acting beta-2 agonists is recommended, while high- or low-dose ICS with LTRAs are recommended as alternative treatments [ 16 , 17 ].…”

Section: Clinical Use Of Montelukast In Children With Asthmamentioning

confidence: 99%

Montelukast use over the past 20 years: monitoring of its effects and safety issues

Lee

Kim

2020

Clin Exp Pediatr

View full text Add to dashboard Cite

Montelukast, a leukotriene receptor antagonist, was launched 20 years ago in Korea. It is recommended as an alternative treatment for asthma in children with mild persistent symptoms or as an add-on treatment to existing low-dose inhaled corticosteroids (ICSs) in children who require additional treatment. However, in the real-world setting, many doctors and patients prefer montelukast over ICSs despite their lower efficacy. Although montelukast is considered to be a safe drug, there are concerns regarding adverse drug reactions, including the rare occurrence of Churg-Strauss syndrome and, despite insufficient data, the possibility of neuropsychiatric events such as anxiety, depression, sleep disturbance, and suicidality. This review identified that montelukast has significantly contributed to asthma control over the past 20 years in Korea and has been critical for reducing asthma severity, especially early wheezing and disease control. Our findings suggest that the effects of montelukast treatment can be monitored by measuring serum eosinophilderived neurotoxin levels.

show abstract

Section: Clinical Use Of Montelukast In Children With Asthmamentioning

confidence: 99%

Montelukast use over the past 20 years: monitoring of its effects and safety issues

Lee

Kim

2020

Clin Exp Pediatr

View full text Add to dashboard Cite

show abstract

“…9 There is a high variability in the quality of clinical practice guidelines (CPG) in general and of the paediatric asthma guidelines in particular globally and locally. [10][11][12] In 2019, the Scottish Intercollegiate Guidelines Network (SIGN) and the British Thoracic Society (BTS) updated the British guideline on the management of asthma (SIGN 158) including the recommendations for the best practice in the management of asthma in adults, including pregnant women and children. This CPG presented recommendations for asthma diagnosis, monitoring, supported self-management, nonpharmacological management, pharmacological management, inhaler devices, management of acute asthma, difficult asthma, asthma in adolescents, asthma in pregnancy, occupational asthma, organisation and delivery of care and provision of information.…”

Section: Introduction and Scopementioning

confidence: 99%

A protocol for adapting a clinical practice guideline for the treatment of paediatric asthma for the Egyptian Pediatric Clinical Practice Guidelines Committee

Abdel Baky,

Youssef,

Elsholkamy

et al. 2024

Clinical and Public Health Guidelines

View full text Add to dashboard Cite

IntroductionPaediatric asthma is a prevalent and chronic respiratory condition affecting children worldwide. This protocol outlines the methodology for developing a clinical practice guideline (CPG) for the management of paediatric asthma. The goal of this guideline is to provide evidence‐based recommendations for healthcare professionals, improving the quality of care and health outcomes for paediatric patients with asthma.MethodsWe will use the ‘Adapted ADAPTE’ adaption method, a systematic approach to adapt existing guidelines, which consists of three phases (setup, adaptation and finalisation phases), nine modules and 24 steps, with adaptations to the process and tools to suit the Egypt healthcare context and resources.QuestionsClinical questions were prepared using the patient population, interventions, professionals, outcomes and healthcare context (PIPOH) model. This CPG protocol addresses critical clinical questions at the heart of effective asthma management in children. It focuses on the diagnosis of paediatric asthma, considering age‐specific clinical presentations and diagnostic tests, assessment of asthma severity, control medications like inhaled corticosteroids, long‐acting β‐agonists and others, with an emphasis on appropriate tools and criteria. The CPG also delves into the realm of long‐term control treatment, exploring the effectiveness and safety of pharmacological and nonpharmacological interventions, while considering individualised needs. Furthermore, it examines strategies for monitoring and adjusting treatment plans over time, ensuring optimal care. These clinical questions form the foundation of the CPG, facilitating evidence‐based care delivery and enhancing health outcomes for paediatric asthma patients.

show abstract

House Dust Mite Tablets Now Officially Accepted as Treatment in GINA: What Is the Evidence and What’s Next?

Luna-Pech

2018

Curr Treat Options Allergy

View full text Add to dashboard Cite

Pediatric asthma treatment

Cited by 3 publications

References 17 publications

Montelukast use over the past 20 years: monitoring of its effects and safety issues

Montelukast use over the past 20 years: monitoring of its effects and safety issues

A protocol for adapting a clinical practice guideline for the treatment of paediatric asthma for the Egyptian Pediatric Clinical Practice Guidelines Committee

House Dust Mite Tablets Now Officially Accepted as Treatment in GINA: What Is the Evidence and What’s Next?

Contact Info

Product

Resources

About